PTCT:NASDAQ
PTC Therapeutics, Inc.
၆၃.၄၆ US$
arrow_downward
-၁.၀၄%(-၀.၆၇) 1D
၆၃.၄၆ US$
၀.၀၀% (၀.၀၀)
bedtimeAfter hours
Closed: အောက် ၂, GMT-၄ ၁၆:၀၀:၀၀ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for PTCT...
Open
၆၄.၈၁ US$
High
၆၅.၄၀ US$
Low
၆၂.၈၀ US$
Mkt. cap
၅၂၉.၆၄ ဋေ
Avg. vol.
၁.၀၉ သန်း
Volume
၈.၉၃ သိန်း
52-wk high
၉၀.၈၆ US$
52-wk low
၆၁.၂၃ US$
EPS
-၀.၅၆ US$
Beta
၀.၄၉
Shares outstanding
၈.၃၅ ကုဋေ
No. of employees
၉၉၁
Open
၆၄.၈၁ US$
High
၆၅.၄၀ US$
Low
၆၂.၈၀ US$
Mkt. cap
၅၂၉.၆၄ ဋေ
Avg. vol.
၁.၀၉ သန်း
Volume
၈.၉၃ သိန်း
52-wk high
၉၀.၈၆ US$
52-wk low
၆၁.၂၃ US$
EPS
-၀.၅၆ US$
Beta
၀.၄၉
Shares outstanding
၈.၃၅ ကုဋေ
No. of employees
၉၉၁
News stories
From web sources and news partners
marketscreener.com
·
ပြီးခဲ့သည့် ၇ မိနစ်
Vertical Aerospace Receives NYSE Noncompliance Notice
Intellia Therapeutics
·
ပြီးခဲ့သည့် ၅၅ မိနစ်
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
·
ပြီးခဲ့သည့် ၄၂ မိနစ်
NeuroSense Provides Update on Nasdaq Listing Compliance
Investor's Business Daily
·
ပြီးခဲ့သည့် ၇ မိနစ်
Nasdaq Pops After Jobs Report; Arrow, Materion, Advantest In Focus
Profile
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees၉၉၁
Founded၁၉၉၈ ဇန် ၁
HeadquartersWarren, နယူးဂျာစီပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websiteptcbio.com